Exagen (NASDAQ:XGN) Major Shareholder Jorey Chernett Sells 58,068 Shares of Company Stock

Exagen Inc. (NASDAQ:XGN – Get Free Report) major shareholder Jorey Chernett sold 58,068 shares of the stock in a transaction on Friday, November 13th. The shares were sold at an average price of $4.08, for a total value of $236,917.44. Following the completion of the transaction, the insider owned 2,529,436 shares of the company’s stock, valued at $10,320,098.88. This trade represents a 2.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Jorey Chernett also recently made the following trade(s):

  • On Thursday, November 12th, Jorey Chernett sold 109,436 shares of Exagen stock. The stock was sold at an average price of $4.65, for a total value of $508,877.40.
  • On Wednesday, November 11th, Jorey Chernett purchased 71,315 shares of Exagen stock. The stock was bought at an average cost of $5.23 per share, for a total transaction of $372,977.45.
  • On Friday, November 6th, Jorey Chernett sold 11,265 shares of Exagen stock. The stock was sold at an average price of $6.14, for a total value of $69,167.10.
  • On Tuesday, November 10th, Jorey Chernett acquired 7,085 shares of Exagen stock. The shares were purchased at an average cost of $5.26 per share, with a total value of $37,267.10.
  • On Monday, November 9th, Jorey Chernett acquired 8,500 shares of Exagen stock. The shares were purchased at an average cost of $6.35 per share, with a total value of $53,975.00.
  • On Monday, October 19th, Jorey Chernett purchased 14,000 shares of Exagen stock. The shares were purchased at an average price of $7.46 per share, for a total transaction of $104,440.00.

Exagen Trading Down 6.3%

Shares of XGN stock traded down $0.28 during trading hours on Friday, reaching $4.13. 3,356,140 shares of the stock traded hands, compared to its average volume of 581,895. Exagen Inc. has a 1-year low of $2.59 and a 1-year high of $9.28. The business has a fifty day moving average price of $7.71 and a 200 day moving average price of $5.13. The company has a quick ratio of 3.18, a current ratio of 3.46 and a debt-to-equity ratio of 1.73. The firm has a market capitalization of $105.36 million, a PE ratio of -5.51 and a beta of 2.25.

Exagen (NASDAQ:XGN – Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Exagen had a negative return on equity of 125.60% and a negative net margin of 25.14%. The firm had revenue of $18.42 million during the quarter, compared to analyst estimates of $18.34 million. On average, equities research analysts forecast that Exagen Inc. will post -0.71 EPS for the current year.

Hedge Funds Weigh In On Exagen

Institutional investors and hedge funds have recently modified their holdings of the stock. Flputnam Investment Management Co. purchased a new stake in shares of Exagen during the 2nd quarter worth about $1,343,000. GSA Capital Partners LLP bought a new stake in shares of Exagen in the 2nd quarter valued at approximately $998,000. Man Group plc bought a new stake in shares of Exagen in the 2nd quarter valued at approximately $778,000. FourWorld Capital Management LLC grew its stake in shares of Exagen by 61.2% in the 1st quarter. FourWorld Capital Management LLC now owns 439,950 shares of the company’s stock valued at $1,320,000 after buying an additional 166,950 shares in the last quarter. Finally, BlackRock Inc. bought a new stake in shares of Exagen in the 2nd quarter valued at approximately $663,000. 75.25% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on XGN shares. B. Riley Financial initiated coverage on Exagen in a research note on Friday, September 11th. They issued a “buy” rating and a $12.00 price objective for the company. Canaccord Genuity Group lowered their target price on Exagen from $11.00 to $9.00 and set a “buy” rating on the stock in a research note on Wednesday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Exagen in a research note on Wednesday, November 4th. Wall Street Zen downgraded Exagen from a “hold” rating to a “sell” rating in a report on Saturday. Finally, TD Cowen increased their price target on shares of Exagen from $10.00 to $11.00 and gave the stock a “buy” rating in a research report on Tuesday, October 13th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.88.

View Our Latest Stock Report on XGN

More Exagen News

Here’s some of the latest news about XGN:

  • Neutral Sentiment: KeyCorp estimates a $0.16-per-share loss for Q4 2026 and a $0.49 loss for 2027. Those are forecasts, not reported results.
  • Negative Sentiment: Major shareholder Jorey Chernett’s recent transactions were net selling: sales of about 178,800 shares outweighed purchases of about 100,900 shares. The sales may concern investors, although Chernett retained a substantial stake. Article: Exagen Stock: Insider Jorey Chernett Sells 109,436 Shares
  • Negative Sentiment: The latest quarter’s loss per share was wider than analysts expected, despite revenue slightly exceeding estimates.

About Exagen

(Get Free Report)

Exagen Inc. is a diagnostics company focused on testing for autoimmune and rheumatic diseases. It develops and provides blood tests intended to help physicians assess and monitor conditions such as systemic lupus erythematosus and other connective tissue diseases. The company’s AVISE test portfolio includes diagnostic and monitoring tests that use proprietary biomarkers to support clinical evaluation. Its offerings are designed to provide information that may help clinicians distinguish among autoimmune conditions and guide patient care.

Featured Articles

Insider Buying and Selling by Quarter for Exagen (NASDAQ:XGN)

Receive News & Ratings for Exagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exagen and related companies with MarketBeat.com's FREE daily email newsletter.